Xos, Inc.'s CFO, Liana Pogosyan, reported a routine tax-withholding transaction where 3,163 shares of common stock were used to cover tax obligations related to restricted stock vesting. This transaction, occurring on May 10, 2026, at $1.89 per share, was a non-market disposition. Following this, Pogosyan directly holds 163,752 shares, including 112,911 unvested restricted stock units.

A longtime Coca-Cola bottling plant in Ventura, operated by Reyes Coca-Cola Bottling LLC, is scheduled to permanently close on July 10, impacting 85 employees. While 78 employees will be reassigned to other facilities, others have the option to apply for open positions within the company. This closure is part of a trend of Coca-Cola facility shutdowns across California, with operations being transferred to other Southern California locations.

Fortinet Inc's CFO, Christiane Ohlgart, sold 238 shares of the company on May 11, 2026, reducing her holdings to 9,818 shares. This sale is part of a pattern over the last year where insiders at Fortinet Inc have primarily been sellers, with 1 insider buy and 15 insider sells. The company's stock is currently trading at $115 per share, which is considered modestly overvalued based on its GF Value of $97.22.

Kuntal Verma, Chief Manufacturing Officer at a First Solar Inc (FSLR) subsidiary, sold 3,671 shares of the company on May 13, 2026, reducing his total holdings to 5,549 shares. This transaction is part of a trend of 65 insider sells and no insider buys for First Solar over the past year. The stock is currently trading at $231.42, and GuruFocus indicates it is modestly undervalued with a price-to-GF-Value ratio of 0.86.

Eric Ashleman, CEO and President of IDEX Corp (IEX), sold 15,385 shares of the company on May 11, 2026, and now holds 66,658 shares. This transaction is part of a pattern where Ashleman has only sold shares (totaling 15,385) over the past year, with no purchases. IDEX Corp's stock was trading at $215.22, with a market cap of $15.707 billion, and is considered fairly valued based on its GF Value.

Elizabeth O'Callahan, Executive Vice President and Chief Administrative Officer at NetApp Inc, sold 1,000 shares of NTAP on May 11, 2026. This transaction continues a trend of insider selling for the company, with 23 insider sells and no buys over the past year. NetApp Inc is currently trading at $117.73, which is considered fairly valued according to its GuruFocus Value.

Altimmune Inc (ALT) reported a strong cash position of approximately USD535 million as of April 2026, bolstered by a USD225 million public offering. Despite increased R&D and G&A expenses leading to a net loss of USD22.6 million in Q1 2026, the company's financial runway is secured through the Phase III MASH 52-week data readout in 2029. Pemvidutide, their lead drug candidate, has received Breakthrough Therapy designation, and its Phase II IMPACT trial showed promising efficacy, with Phase III trials aligned with regulatory feedback from the FDA and EMA.

David Maughan, COO of DaVita Kidney Care, sold 20,529 shares of DaVita Inc (DVA) on May 12, 2026, reducing his holdings to 94,105 shares. This sale is part of a trend of nine insider sells and no buys at the company over the past year. DaVita Inc, trading at $199.22 with a market cap of $12.715 billion, is considered modestly overvalued based on its GuruFocus Value of $171.68.

A federal judge denied BeiGene Ltd.'s motion to dismiss a trade secret lawsuit filed by AbbVie Inc. AbbVie accuses BeiGene of misappropriating confidential information related to cancer treatment compound designs by hiring a former AbbVie scientist. The court ruled that AbbVie's complaint provided sufficient details and that BeiGene's dismissal arguments were not compelling.

Inhibrx Biosciences announced positive interim Phase 2 results for INBRX-106 combined with pembrolizumab in head and neck cancer, showing a 44% confirmed objective response rate and deeper tumor reductions compared to pembrolizumab alone. The study demonstrated robust T-cell expansion and a manageable safety profile. The company plans to advance to Phase 3 and explore broader indications for OX40 agonism.